Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Viatris Inc (VTRS)

Viatris Inc (VTRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,555,319
  • Shares Outstanding, K 1,151,393
  • Annual Sales, $ 14,300 M
  • Annual Income, $ -3,515 M
  • EBIT $ 274 M
  • EBITDA $ 6,009 M
  • 60-Month Beta 0.78
  • Price/Sales 1.09
  • Price/Cash Flow 1.83
  • Price/Book 1.06

Options Overview Details

View History
  • Implied Volatility 47.59% (+1.57%)
  • Historical Volatility 41.77%
  • IV Percentile 88%
  • IV Rank 48.70%
  • IV High 69.86% on 04/04/25
  • IV Low 26.44% on 12/23/25
  • Expected Move (DTE 5) 0.82 (6.04%)
  • Put/Call Vol Ratio 8.45
  • Today's Volume 5,672
  • Volume Avg (30-Day) 6,801
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 191,918
  • Open Int (30-Day) 138,213
  • Expected Range 12.69 to 14.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.52
  • Number of Estimates 4
  • High Estimate 0.56
  • Low Estimate 0.45
  • Prior Year 0.50
  • Growth Rate Est. (year over year) +4.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.48 +0.22%
on 03/13/26
16.47 -17.97%
on 02/26/26
-2.26 (-14.33%)
since 02/13/26
3-Month
11.42 +18.30%
on 12/17/25
16.47 -17.97%
on 02/26/26
+1.86 (+15.97%)
since 12/12/25
52-Week
6.85 +97.23%
on 04/10/25
16.47 -17.97%
on 02/26/26
+4.53 (+50.45%)
since 03/13/25

Most Recent Stories

More News
Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings?

Viatris (VTRS): Buy, Sell, or Hold Post Q4 Earnings?

VTRS : 13.51 (-2.10%)
Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4

Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4

VTRS : 13.51 (-2.10%)
Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025

VTRS : 13.51 (-2.10%)
Viatris: Q4 Earnings Snapshot

Viatris: Q4 Earnings Snapshot

VTRS : 13.51 (-2.10%)
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

PITTSBURGH , Feb. 26, 2026 /PRNewswire/ --  Viatris Inc . (Nasdaq: VTRS) today announced robust financial results for the fourth quarter and full year 2025. The Company also announced it has...

VTRS : 13.51 (-2.10%)
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

PITTSBURGH , Feb. 26, 2026 /PRNewswire/ -- Viatris Inc . (Nasdaq: VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per...

VTRS : 13.51 (-2.10%)
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia

FDA PDUFA Goal Date Set for October 17, 2026

VTRS : 13.51 (-2.10%)
Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow

Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow

VTRS : 13.51 (-2.10%)
1 Unpopular Stock That Should Get More Attention and 2 Facing Challenges

1 Unpopular Stock That Should Get More Attention and 2 Facing Challenges

KMB : 98.84 (+1.04%)
WDC : 272.29 (+4.25%)
VTRS : 13.51 (-2.10%)
2 Value Stocks Worth Your Attention and 1 We Brush Off

2 Value Stocks Worth Your Attention and 1 We Brush Off

FRSH : 8.13 (+2.26%)
VTRS : 13.51 (-2.10%)
BRBR : 16.83 (+0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor...

See More

Key Turning Points

3rd Resistance Point 14.32
2nd Resistance Point 14.14
1st Resistance Point 13.83
Last Price 13.51
1st Support Level 13.34
2nd Support Level 13.16
3rd Support Level 12.85

See More

52-Week High 16.47
Last Price 13.51
Fibonacci 61.8% 12.80
Fibonacci 50% 11.66
Fibonacci 38.2% 10.52
52-Week Low 6.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar